GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jiangsu Cowin Biotech Co Ltd (SHSE:688426) » Definitions » EBIT

Jiangsu Cowin Biotech Co (SHSE:688426) EBIT : ¥-172.1 Mil (TTM As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Jiangsu Cowin Biotech Co EBIT?

Jiangsu Cowin Biotech Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ¥-46.8 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥-172.1 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Jiangsu Cowin Biotech Co's annualized ROC % for the quarter that ended in Sep. 2024 was -18.07%. Jiangsu Cowin Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -31.87%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Jiangsu Cowin Biotech Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -12.26%.


Jiangsu Cowin Biotech Co EBIT Historical Data

The historical data trend for Jiangsu Cowin Biotech Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Cowin Biotech Co EBIT Chart

Jiangsu Cowin Biotech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 8.68 126.56 146.45 197.33 -91.29

Jiangsu Cowin Biotech Co Quarterly Data
Dec18 Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.07 -68.21 -34.95 -22.10 -46.82

Competitive Comparison of Jiangsu Cowin Biotech Co's EBIT

For the Biotechnology subindustry, Jiangsu Cowin Biotech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Cowin Biotech Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jiangsu Cowin Biotech Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Jiangsu Cowin Biotech Co's EV-to-EBIT falls into.


;
;

Jiangsu Cowin Biotech Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-172.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jiangsu Cowin Biotech Co  (SHSE:688426) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Jiangsu Cowin Biotech Co's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-179.944 * ( 1 - 2.71% )/( (964.609 + 972.878)/ 2 )
=-175.0675176/968.7435
=-18.07 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1735.144 - 43.903 - ( 726.632 - max(0, 64.46 - 992.995+726.632))
=964.609

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1670.367 - 44.153 - ( 653.336 - max(0, 62.782 - 895.443+653.336))
=972.878

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Jiangsu Cowin Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-187.276/( ( (387.68 + max(211.595, 0)) + (386.667 + max(189.134, 0)) )/ 2 )
=-187.276/( ( 599.275 + 575.801 )/ 2 )
=-187.276/587.538
=-31.87 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(61.604 + 36.576 + 163.407) - (43.903 + 0 + 6.089)
=211.595

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(58.073 + 41.491 + 137.778) - (44.153 + 0 + 4.055)
=189.134

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Jiangsu Cowin Biotech Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-172.08/1404.141
=-12.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jiangsu Cowin Biotech Co EBIT Related Terms

Thank you for viewing the detailed overview of Jiangsu Cowin Biotech Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiangsu Cowin Biotech Co Business Description

Traded in Other Exchanges
N/A
Address
No. 1 Yaocheng Avenue, 4th Floor, TQB Building, Jiangsu Province, Taizhou, CHN, 225300
Jiangsu Cowin Biotech Co Ltd is a national high-tech enterprise with independent intellectual property rights based in the field of life sciences. It provides innovative biological products and services to in vitro diagnostic users. The product line mainly includes molecular diagnostic raw materials enzymes, nucleic acid collection and protection agents, nucleic acid extraction kits, molecular diagnostic detection reagents and others.
Executives
Yin Jian Feng Director
Zhuang Zhi Hua Directors, senior managers

Jiangsu Cowin Biotech Co Headlines

No Headlines